Fischer Medical Ventures Ltd

As of March 31, 2026, Fischer Medical Ventures Ltd carries a market capitalization of 26.45B, placing it among publicly traded companies globally. Its enterprise value stands at 27.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Fischer Medical Ventures Ltd has 654.52M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Fischer Medical Ventures Ltd maintains a current ratio of 1.62, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Fischer Medical Ventures Ltd recorded 119.76M in income tax expense.

As of the close on October 22, 2026, Fischer Medical Ventures Ltd's stock has declined approximately 75.87% over the past 52 weeks. The 50-day moving average sits at 34.24, while the 200-day moving average is 37.02.

As of March 31, 2026, Fischer Medical Ventures Ltd holds 250.46M in cash and equivalents against 1.07B in total debt, resulting in a net debt position of 604.71M. Total book value stands at 3.84B, with working capital of 1.60B providing operational flexibility.

Fischer Medical Ventures Ltd's most recent stock split took place on September 12, 2025 with a 1:10 split ratio.